NA
GSK icon

Navellier & Associates’s GSK GSK Stock Holding History

Navellier & Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-8,381
Closed -$560K – 338
2014
Q2 		$560K Buy
8,381
+2,509
+43% +$170K 0.03% 170
2014
Q1 		$392K Sell
5,872
-142
-2% -$9.6K 0.02% 211
2013
Q4 		$401K Buy
6,014
+1,127
+23% +$73.1K 0.02% 216
2013
Q3 		$306K Buy
4,887
+271
+6% +$17.4K 0.01% 236
2013
Q2 		$288K Buy
+4,616
New +$293K 0.01% 215

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Navellier & Associates's GSK Position: Q3 2014 in Review

Navellier & Associates sold out of GSK (GSK) in Q3 2014, closing a stake of 8,381 shares — an estimated $560K sold.

Navellier & Associates first reported a position in GSK in Q2 2013 and held it in 5 quarters. The position peaked at $560K in Q2 2014. 701 funds tracked by Wall St. Rank hold GSK as of Q3 2014.

  • Navellier & Associates reported no remaining GSK position as of Q3 2014 after selling out during the quarter.
  • Navellier & Associates sold 8,381 GSK shares in Q3 2014, an estimated $560K.
  • Navellier & Associates first reported a position in GSK in Q2 2013 and held it in 5 quarters.
  • Navellier & Associates's GSK position peaked at $560K in Q2 2014.
  • 701 funds tracked by Wall St. Rank held GSK as of Q3 2014.

Based on Navellier & Associates's 13F filing for Q3 2014, filed 7 Oct 2014.